Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells

[1]  P. Sorensen,et al.  Translational control of aberrant stress responses as a hallmark of cancer , 2018, The Journal of pathology.

[2]  Shreyaskumar R Patel,et al.  Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment , 2018, Current Oncology Reports.

[3]  Nahum Sonenberg,et al.  Beyond molecular tumor heterogeneity: protein synthesis takes control , 2018, Oncogene.

[4]  V. Lewis,et al.  Current and future therapeutic approaches for osteosarcoma , 2018, Expert review of anticancer therapy.

[5]  B. Groner,et al.  Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.

[6]  A. Grothey,et al.  Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor , 2017, Drugs.

[7]  M. Yaszemski,et al.  2‐Methoxyestradiol‐Mediated Induction of Frzb Contributes to Cell Death and Autophagy in MG63 Osteosarcoma Cells , 2017, Journal of cellular biochemistry.

[8]  Simion I. Chiosea,et al.  Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. , 2017, JCI insight.

[9]  S. Bielack,et al.  Novel insights and therapeutic interventions for pediatric osteosarcoma. , 2017, Future oncology.

[10]  A. Sudo,et al.  STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma , 2016, International journal of oncology.

[11]  J. Grandis,et al.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. , 2016, Oral oncology.

[12]  M. Yaszemski,et al.  The estrogen metabolite 2-methoxyestradiol regulates eukaryotic initiation factor 4E (eIF4E) and inhibits protein synthesis in MG63 osteosarcoma cells , 2016, Genes & diseases.

[13]  Chunxiao Liu,et al.  Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin , 2016, Cancer medicine.

[14]  Sang-Gu Hwang,et al.  STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers , 2016, Oncotarget.

[15]  N. Sonenberg,et al.  Signalling to eIF4E in cancer , 2015, Biochemical Society transactions.

[16]  H. A. Rogoff,et al.  Suppression of cancer relapse and metastasis by inhibiting cancer stemness , 2015, Proceedings of the National Academy of Sciences.

[17]  A. Tee,et al.  mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 , 2014, Oncogene.

[18]  D. Miranda-Saavedra,et al.  Genomic and computational approaches to dissect the mechanisms of STAT3’s universal and cell type-specific functions , 2013, JAK-STAT.

[19]  H. Sellier,et al.  How should we define STAT3 as an oncogene and as a potential target for therapy? , 2013, JAK-STAT.

[20]  M. Tkach,et al.  p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. , 2013, Endocrine-related cancer.

[21]  M. Yaszemski,et al.  RNA-Dependent Protein Kinase Is Essential for 2-Methoxyestradiol-Induced Autophagy in Osteosarcoma Cells , 2013, PloS one.

[22]  A. Folpe,et al.  Common musculoskeletal tumors of childhood and adolescence. , 2012, Mayo Clinic proceedings.

[23]  M. Yaszemski,et al.  Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells , 2012, BMC Cancer.

[24]  K. Wood,et al.  Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma , 2010, Spine.

[25]  H. Mankin,et al.  Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated‐Stat3 correlates with poor prognosis , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[26]  David B. Pierce,et al.  Protein kinase Cε mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression and cell invasion in various human cancer cell lines via integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2) , 2010, Oncogene.

[27]  Z. Duan,et al.  Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway , 2010, BMC Cancer.

[28]  B. Fuchs,et al.  Osteoblastic and Osteolytic Human Osteosarcomas can be Studied With a New Xenograft Mouse Model Producing Spontaneous Metastases , 2009, Cancer investigation.

[29]  Jiayuh Lin,et al.  Characterization of STAT3 activation and expression in canine and human osteosarcoma , 2009, BMC Cancer.

[30]  E. Hurt,et al.  Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. , 2008, Cancer research.

[31]  M. Clemens,et al.  Regulation of translation factors eIF4GI and 4E-BP1 during recovery of protein synthesis from inhibition by p53 , 2007, Cell Death and Differentiation.

[32]  M. Yaszemski,et al.  Double‐Stranded RNA‐Dependent Protein Kinase Is Involved in 2‐Methoxyestradiol—Mediated Cell Death of Osteosarcoma Cells , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[34]  A. Maran,et al.  17beta-estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. , 2005, Endocrinology.

[35]  M. Clemens,et al.  Targets and mechanisms for the regulation of translation in malignant transformation , 2004, Oncogene.

[36]  F. Hoffer,et al.  NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. , 1996, Oncology.

[37]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[38]  E. Holmes,et al.  Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.